Triethylenetetramine
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Triethylenetetramine
- Pharmacist Assessment Report
- Triethylenetetramine: Thyroid gland undifferentiated (anaplastic) carcinoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Triethylenetetramine: Thyroid gland undifferentiated (anaplastic) carcinoma
One-Sentence Summary
Triethylenetetramine (trientine) is a copper chelator, originally used to treat Wilson disease. The TxGNN model predicts it may be effective for anaplastic thyroid carcinoma, but no clinical trials and no publications were found to support this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Thyroid gland undifferentiated (anaplastic) carcinoma |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, triethylenetetramine is a copper chelator that is established in Wilson disease, a copper-overload disorder. Mechanistically, it may be applicable to anaplastic thyroid carcinoma.
A plausible but unvalidated link is copper depletion. Copper is a cofactor in angiogenesis and tumour signalling, and copper-depleting agents have been explored preclinically in several cancers. The high TxGNN score is a computational prediction only. Because the original mechanism data is missing, the link cannot be checked against the drug’s known mechanism.
Other high-scoring predictions from the same model run are also unsupported by evidence:
- Idiopathic copper-associated cirrhosis is the most mechanistically coherent. Copper chelation has a clear rationale in copper-overload liver disease, and this is flagged as a research question. A targeted literature search is a reasonable next step.
- Renal cell carcinoma subtypes (TFE3-fusion and neuroblastoma-associated): the scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. This is not independent validation.
- Portal hypertension, portal vein thrombosis, hepatopulmonary syndrome and hepatic porphyria: the scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related hepatic and metabolic diseases, not biological evidence. No supported mechanism was identified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13124R | Trientine Waymade | Oral capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine) | Not recorded in the data compiled for this report |
Safety Considerations
- Drug interactions: 27 interactions were identified, and the 20 detailed entries are all rated Moderate. They fall into three groups:
- Calcium salts: phosphate, acetate, carbonate, citrate, glubionate, gluconate and lactate.
- Magnesium salts: oxide, carbonate, chloride and citrate.
- Iron and trace minerals: iron, ferrous fumarate, ferrous gluconate, ferrous sulfate, iron protein succinylate, tetraferric tricitrate, selenium, manganese sulfate and copper gluconate. These are consistent with metal-binding (chelation) interactions, so dose separation from mineral products is likely to matter.
- Knowledge-graph contraindication signals (from the model’s graph, not product label text, so they need confirmation against the PI): hypertension, long QT syndrome and torsades de pointes, liver failure, drug-induced liver injury, adrenocortical insufficiency, hypothyroidism, myocardial infarction, hyperbilirubinaemia, diarrhoeal disease, hereditary haemorrhagic telangiectasia, and peripheral vascular disease, among others.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as label data was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score (L5). No trials or publications were found, and the original mechanism data is missing. Label-based safety data is also unavailable, so safety screening cannot proceed.
To proceed, the following is needed:
- Obtain the TGA PI (warnings, contraindications, approved indication text) for ARTG 13124R.
- Obtain mechanism of action data from DrugBank.
- Run a targeted literature search on copper chelation in anaplastic thyroid carcinoma and other cancers.
- Prioritise the copper-associated cirrhosis question, which has the strongest mechanistic rationale, for a separate review.
- Define a plan for managing mineral interactions and monitoring copper status if any new use is pursued.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.